Technical Analysis for SHPG - Shire plc
|Grade||Last Price||% Change||Price Change|
SHPG closed down 3.23 percent on Monday, August 21, 2017, on 2.2 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Trend Table & Recent Alerts
|See historical SHPG trend table...|
|Date||Alert Name||Type||% Chg|
|Aug 21||New 52 Week Low||Other||0.00%|
|Aug 21||New 52 Week Closing Low||Bearish||0.00%|
|Aug 18||New 52 Week Low||Other||-3.23%|
|Aug 18||Hammer Candlestick||Bullish||-3.23%|
|Aug 18||New 52 Week Closing Low||Bearish||-3.23%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SHPG news...
|52 Week High||209.22|
|52 Week Low||144.18|
|200-Day Moving Average||171.7411|
|50-Day Moving Average||162.3566|
|20-Day Moving Average||156.8405|
|10-Day Moving Average||148.758|
|Average True Range||3.4287|
|Chandelier Exit (Long, 3 ATRs)||161.3039|
|Chandelier Exit (Short, 3 ATRs)||149.6461|
|Upper Bollinger Band||175.3582|
|Lower Bollinger Band||138.3228|
|Percent B (%b)||0.07|
|MACD Signal Line||-4.4651|